| Sandra Ferrill, LPN | |
|
8321 Amoka Dr, Diamondhead, MS 39525-4060 | |
| (228) 363-3606 | |
| Not Available |
| Full Name | Sandra Ferrill |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 8321 Amoka Dr, Diamondhead, Mississippi |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265995740 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 20120534 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sandra Ferrill, LPN 8321 Amoka Dr, Diamondhead, MS 39525-4060 Ph: () - | Sandra Ferrill, LPN 8321 Amoka Dr, Diamondhead, MS 39525-4060 Ph: (228) 363-3606 |
News Archive
Exoskeleton technology leader, ARGO Medical Technologies, along with mobility solutions provider, Cyclone Technologies, announced today that Claire Lomas has become the first person to take home an exoskeleton system for personal use. Claire demonstrated her personal ReWalk⢠at the annual International Spinal Cord Society (ISCoS) meeting held at the Queen Elizabeth II Conference Center.
A team of scientists from government, academia and private industry has developed a novel treatment that protects mice from infection with the bacterium that causes tularemia, a highly infectious disease of rodents, sometimes transmitted to people, and also known as rabbit fever. In additional experiments with human immune cells, the treatment also demonstrated protection against three other types of disease-causing bacteria that, like the tularemia bacteria, occur naturally, can be highly virulent, and are considered possible agents of bioterrorism.
Patients with cancer in low-income nations present for surgical treatment at a young age, advanced stage of disease, and often receive palliative rather than curative procedures, suggests a study in Malawi.
Mylan Inc. today is pleased to announce that its subsidiary Matrix Laboratories Ltd. has been notified by the World Health Organization (WHO) Prequalification of Medicines Programme that the WHO has withdrawn its notice of concern for Matrix Unit 8, which is located in the Vizianagaram District of India, with no remaining concerns outstanding.
› Verified 7 days ago